Printer Friendly

CARDIAC SCIENCE INC. LIFTS THE RESTRICTION ON TRANSFER OF SHARES AND RAISES ADDITIONAL FUNDS

 CARDIAC SCIENCE INC. LIFTS THE RESTRICTION
 ON TRANSFER OF SHARES AND RAISES ADDITIONAL FUNDS
 IRVINE, Calif., May 5 /PRNewswire/ -- Cardiac Science Inc. announced today that the company's board of directors will lift the restriction on transfers on the 4,723,263 shares of the company's common stock spun-out to Cytocare Inc. (NASDAQ: CYTI) shareholders of record as of July 8, 1991, effective May 15, 1992. The company currently has 6,997,448 shares issued and outstanding.
 The company also announced it has completed a new round of venture capital funding amounting to $250,000 immediately and an added commitment for an additional $250,000.
 Cardiac Science Inc. is a developer of ambulatory and bedside automatic external cardioverter defibrillator devices to treat persons suffering from life threatening ventricular arrhythmias which causes sudden cardiac death -- the leading killer in the United States.
 A copy of the company's annual report filed with the Securities and Exchange Commission on Form 10-K is available without charge by writing to:
 Corporate Secretary
 Cardiac Science Inc.
 9975 Toledo
 Irvine, CA 92718
 -0- 5/5/92
 /CONTACT: Howard K. Cooper, chairman, CEO and president of Cardiac Science, 714-587-0357/
 (CYTI) CO: Cardiac Science Inc.; Cytocare Inc. ST: California IN: HEA SU:


DM-EH -- LA007 -- 6388 05/05/92 09:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:211
Previous Article:ATI MEDICAL INC. SHAREHOLDERS APPROVE PROPOSED MERGER
Next Article:PITTSBURGH NEWSPAPER UNIONS: TOYS 'R' US BOYCOTT


Related Articles
Cardiac Science Completes $8.7 Million Financing.
CARDIAC-SCIENCE CLOSES $20.8 MILLION IN PRIVATE PLACEMENT.
Cardiac Science Granted Additional U.S. Patent Covering Automatic External Defibrillator Technology.
Cardiac Science's Acquisition of Survivalink and Artema on Course to Close By End of September.
Cardiac Science Completes Financings; $38 Million Raised in Two Separate Private Placements.
Cardiac Science Acquires Complient Corporation; AED Training Services to Provide Annually Recurring Revenue.
Cardiac Science Raises $8.4 Million in Private Placement of Common Stock.
Canadian Coast Guard Equips Nationwide Search and Rescue Vessels With Cardiac Science's Powerheart(R) AEDs.
Cardiac Science Raises $12.4 Million in Private Placement Led by Perseus.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters